Marogna Maurizio, Spadolini Igino, Massolo Alessandro, Zanon Pietro, Berra Daniele, Chiodini Elena, Canonica Walter G, Passalacqua Giovanni
Pneumology Unit, Cuasso al Monte, Macchi Hospital Foundation, Varese, Italy.
Ann Allergy Asthma Immunol. 2007 Mar;98(3):274-80. doi: 10.1016/S1081-1206(10)60718-1.
Sublingual immunotherapy (SLIT) has proven efficacy in treating respiratory allergy.
To compare the clinical and functional effects and the effect on nasal eosinophils of SLIT with either single or combination allergens.
We performed an open-labeled, controlled, 4 parallel-group randomized study with 58 patients sensitized to birch and grasses only who had rhinitis and bronchial hyperreactivity in both pollen seasons. Patients were recruited for the study from January 1, 1999, to June 30, 2001. The patients received SLIT for birch, SLIT for grass, SLIT for birch and grass, or drugs only. Symptom and medication scores, forced expiratory volume in 1 second, bronchial hyperreactivity, and nasal eosinophil counts were evaluated in both pollen seasons at baseline and after 2 and 4 years.
Ten patients dropped out and 48 completed the study. No change in all the considered parameters vs baseline was seen in patients treated with drugs only. Those patients receiving SLIT for grass or birch had a significant clinical improvement and nasal eosinophil reduction vs baseline and vs patients who did not receive SLIT in the target season (P < .01) but also in the unrelated pollen season (P < .05). The patients receiving SLIT for grass and birch improved as well, and their improvement in clinical symptoms and inflammation was significantly greater than in patients treated with SLIT for the single allergens. Minor changes were seen in the forced expiratory volume in 1 second, since it remained within the reference range in the whole population.
In patients sensitized to grass and birch, SLIT with the 2 allergens provided the best clinical results. Nevertheless, SLIT with birch only or grass only also provided a measurable improvement in the grass season and birch season, respectively.
舌下免疫疗法(SLIT)已被证明在治疗呼吸道过敏方面有效。
比较单一过敏原或联合过敏原的舌下免疫疗法在临床和功能方面的效果以及对鼻嗜酸性粒细胞的影响。
我们进行了一项开放标签、对照、4平行组随机研究,纳入58例仅对桦树和草过敏且在两个花粉季节均患有鼻炎和支气管高反应性的患者。患者于1999年1月1日至2001年6月30日被招募参加该研究。患者接受桦树过敏原舌下免疫疗法、草过敏原舌下免疫疗法、桦树和草过敏原舌下免疫疗法或仅接受药物治疗。在两个花粉季节的基线以及2年和4年后,对症状和用药评分、一秒用力呼气量、支气管高反应性和鼻嗜酸性粒细胞计数进行评估。
10例患者退出研究,48例完成研究。仅接受药物治疗的患者与基线相比,所有考虑的参数均无变化。接受草或桦树过敏原舌下免疫疗法的患者与基线相比以及与在目标季节未接受舌下免疫疗法的患者相比,临床症状有显著改善,鼻嗜酸性粒细胞减少(P < 0.01),在非相关花粉季节也有改善(P < 0.05)。接受桦树和草过敏原舌下免疫疗法的患者也有改善,其临床症状和炎症的改善明显大于接受单一过敏原舌下免疫疗法的患者。一秒用力呼气量有轻微变化,因为在整个人群中其仍在参考范围内。
在对草和桦树过敏的患者中,使用两种过敏原的舌下免疫疗法提供了最佳临床效果。然而,仅使用桦树或仅使用草的舌下免疫疗法分别在草季节和桦树季节也提供了可测量的改善。